Caitlin John’s GT Biopharma GTBP Stock Holding History

Caitlin John’s Portfolio GTBP Stock Details GTBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$6.73K	Hold	16,500	–	–	﹤0.01%	581
2025 Q4	$13K	Buy	+16,500	New	+$11.7K	0.01%	504

Other funds holding GTBP

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

AAP

Arax Advisory Partners Denver, Colorado $3.54B AUM 19.14% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

SWM

SeaCrest Wealth Management Purchase, New York $903M AUM 47.26% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

INVST Indianapolis, Indiana $886M AUM 21.79% 1-Year Est. Return

Caitlin John's GTBP Position: Q1 2026 in Review

Caitlin John held its GT Biopharma (GTBP) position steady in Q1 2026 at 16,500 shares worth $6.73K. The position accounts for ﹤0.01% of the portfolio, ranked #581.

Caitlin John first reported a position in GTBP in Q4 2025 and has held it in 2 quarters since. The position peaked at $13K in Q4 2025. 42 funds tracked by Wall St. Rank hold GTBP as of Q1 2026.

Caitlin John held 16,500 shares of GT Biopharma worth $6.73K as of Q1 2026.
Caitlin John left its GT Biopharma share count unchanged in Q1 2026.
GT Biopharma made up ﹤0.01% of Caitlin John's portfolio in Q1 2026, its #581 holding.
Caitlin John first reported a position in GT Biopharma in Q4 2025 and has held it in 2 quarters since.
Caitlin John's GT Biopharma position peaked at $13K in Q4 2025.
42 funds tracked by Wall St. Rank held GT Biopharma as of Q1 2026.

Based on Caitlin John's 13F filing for Q1 2026, filed 13 May 2026.